Dicot Pharma presents interim report Q3 2026 and invites to a webcast

Third quarter 2026

• Net sales amounted to SEK 0.0 (0.0) million
• The result after financial items amounted to SEK -25.2 (-16.1) million
• Earnings per share amounted to SEK -0.01 (-0.01)

“With funding for the Phase 2b secured, we are now putting the final pieces in place to initiate the study this year,” comments Elin Trampe, CEO Dicot Pharma

Significant events during the third quarter

• On 17 August, the company announced that a clinical trial application had been submitted in the EU for the phase 2b study of the drug candidate LIB-01, which is to be conducted in the United States and Europe. The study is intended to evaluate the efficacy of different doses of LIB-01 following repeated dosing.
• On 19 August, Dicot Pharma announced that three abstracts on LIB-01 had been selected for oral presentation at the Sexual Medicine Society of North America’s 27th Annual Fall Scientific Meeting, held on 8–11 October 2026 in Orlando, USA. All three abstracts were to be presented in the conference’s innovation section.
• On 1 September, Cecilia Driving assumed the role of Chief Financial Officer (CFO), succeeding Björn Petersson, who had served on a consultancy basis. Cecilia Driving has extensive and broad experience as a CFO, with particular expertise in capital markets, investor relations and business development

Significant events after the reporting period

• Dicot Pharma participated in the SMSNA conference held in Orlando, USA, on 8–11 October. Three abstracts on LIB-01 were presented by Chief Scientific Officer Charlotta Gauffin and the internationally recognised experts in sexual medicine; Dr Harin Padma-Nathan, whose previous roles include principal investigator in the United States for Viagra and Cialis and as Professor of Urology at the University of Southern California, and Dr Arthur Burnett, Professor of Urology at Johns Hopkins School of Medicine, Patrick C. Walsh Distinguished Professor of Urology, and well known for his contribution to elucidating Viagra’s mechanism of action. On 13 October, the company held a webcast to share the presentations and the company’s reflections from SMSNA. The webcast is available afterward via www.dicotpharma.com.
• A new patent has been granted in 25 European countries covering the manufacturing process for its drug candidate LIB-01. The patent strengthens the intellectual property protection in an important market until 2043.

The interim report will be presented by CEO Elin Trampe and CFO Cecilia Driving in a broadcast from Direkt Studio today October 28 at 01:00 p.m. CEST. The broadcast will be available at https://www.dicotpharma.com/en/media/films/ and can also be viewed later.